Recruiting PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT05552157

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU)

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease

Sponsor: Alzheimer's Association

Conditions Alzheimers Disease Alzheimers Disease, Familial Dementia

Interventions Matching Placebo (Remternetug) Remternetug (SC)

Updated 13 times since 2022 Last updated: Feb 11, 2026 Started: Nov 22, 2024 Primary completion: Mar 30, 2034 Completion: Aug 30, 2034

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Alzheimers Disease and Alzheimers Disease, Familial and is currently actively recruiting participants. Alzheimer's Association leads this study, which shows 13 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

13 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2/PHASE3
Dec 2025 — Feb 2026 [monthly]

Recruiting PHASE2/PHASE3
Sep 2025 — Dec 2025 [monthly]

Recruiting PHASE2/PHASE3
May 2025 — Sep 2025 [monthly]

Recruiting PHASE2/PHASE3
Dec 2024 — May 2025 [monthly]

Recruiting PHASE2/PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 8 earlier versions

Nov 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE2/PHASE3
Oct 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE2/PHASE3

Status: Suspended → Not Yet Recruiting
Sep 2024 — Oct 2024 [monthly]

Suspended PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Apr 2024 — Jul 2024 [monthly]

Suspended PHASE2_PHASE3
Feb 2023 — Apr 2024 [monthly]

Suspended PHASE2_PHASE3

Status: Recruiting → Suspended
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Jan 2023 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alzheimer's Association
Eli Lilly and Company
National Institute on Aging (NIA)
Washington University School of Medicine

Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Atlanta, United States , Barcelona, Spain , Birmingham, United States , Brescia, Italy , Bron, France , Christchurch, New Zealand , Ciudad Autonoma de Buenos Aire, Argentina , Dallas, United States , Florence, Italy and 25 more locations